BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 36523785)

  • 1. Identification of severe acute respiratory syndrome coronavirus 2 breakthrough infections by anti-nucleocapsid antibody among fully vaccinated non-healthcare workers during the transition from the delta to omicron wave.
    Dai YC; Lin YC; Ching LL; Tseng AC; Qin Y; Nerurkar VR; Wang WK
    Front Med (Lausanne); 2022; 9():1019490. PubMed ID: 36523785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and immunological benefits of full primary COVID-19 vaccination in individuals with SARS-CoV-2 breakthrough infections: A prospective cohort study in non-hospitalized adults.
    Prelog M; Jeske SD; Asam C; Fuchs A; Wieser A; Gall C; Wytopil M; Mueller-Schmucker SM; Beileke S; Goekkaya M; Kling E; Geldmacher C; Rubio-Acero R; Plank M; Christa C; Willmann A; Vu M; Einhauser S; Weps M; Lampl BMJ; Almanzar G; Kousha K; Schwägerl V; Liebl B; Weber B; Drescher J; Scheidt J; Gefeller O; Messmann H; Protzer U; Liese J; Hoelscher M; Wagner R; Überla K; Steininger P;
    J Clin Virol; 2024 Feb; 170():105622. PubMed ID: 38091664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Antibody Responses and Identification of Vaccine Breakthrough Infections Among Healthcare Workers Using Nucleocapsid Immunoglobulin G.
    Anderson M; Stec M; Gosha A; Mohammad T; Boler M; Tojo Suarez R; Behun D; Landay A; Cloherty G; Moy J
    J Infect Dis; 2022 Nov; 226(11):1934-1942. PubMed ID: 36263799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Omicron infection increases IgG binding to spike protein of predecessor variants.
    Mahalingam G; Periyasami Y; Arjunan P; Subaschandrabose RK; Mathivanan TV; Mathew RS; Devi RKT; Premkumar PS; Muliyil J; Srivastava A; Moorthy M; Marepally S
    J Med Virol; 2023 Feb; 95(2):e28419. PubMed ID: 36546401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics of COVID-19 Breakthrough Infections among Vaccinated Individuals and Associated Risk Factors: A Systematic Review.
    Gopinath S; Ishak A; Dhawan N; Poudel S; Shrestha PS; Singh P; Xie E; Tahir P; Marzaban S; Michel J; Michel G
    Trop Med Infect Dis; 2022 May; 7(5):. PubMed ID: 35622708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Multivariant Surrogate Virus Neutralization Test Demonstrates Distinct SARS-CoV-2-Specific Antibody Responses in People Living with HIV after a Fourth Monovalent mRNA Vaccination or an Omicron Breakthrough Infection.
    Springer DN; Daller S; Knappik M; Prüger K; Hartl S; Breyer-Kohansal R; Puchhammer-Stöckl E; Aberle JH; Weseslindtner L; Breyer MK
    Diagnostics (Basel); 2024 Apr; 14(8):. PubMed ID: 38667468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SARS-CoV-2 Vaccine Breakthrough Infections of Omicron and Delta Variants in Healthcare Workers.
    Regenhardt E; Kirsten H; Weiss M; Lübbert C; Stehr SN; Remane Y; Pietsch C; Hönemann M; von Braun A
    Vaccines (Basel); 2023 May; 11(5):. PubMed ID: 37243062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neutralization sensitivity, fusogenicity, and infectivity of Omicron subvariants.
    Wang XJ; Yao L; Zhang HY; Zhu KL; Zhao J; Zhan BD; Li YK; He XJ; Huang C; Wang ZY; Jiang MD; Yang P; Yang Y; Wang GL; Wang SQ; Dai EH; Gao HX; Ma MJ
    Genome Med; 2022 Dec; 14(1):146. PubMed ID: 36581867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced antibody responses in fully vaccinated individuals against pan-SARS-CoV-2 variants following Omicron breakthrough infection.
    Jeong HW; Kim SM; Jung MK; Noh JY; Yoo JS; Kim EH; Kim YI; Yu K; Jang SG; Gil J; Casel MA; Rare R; Choi JH; Kim HS; Kim JH; Um J; Kim C; Kim Y; Chin BS; Jung S; Choi JY; Song KH; Kim YD; Park JS; Song JY; Shin EC; Choi YK
    Cell Rep Med; 2022 Oct; 3(10):100764. PubMed ID: 36182684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Longitudinal Monitoring of Seroconversion Status in SARS-CoV-2 RT-PCR Positive Healthcare Workers].
    Ersoy L; Tezcan Ülger S; Gülbudak H; Yaşar N; Yapıcı G; Aslan G
    Mikrobiyol Bul; 2022 Jan; 56(1):114-123. PubMed ID: 35088965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigating SARS-CoV-2 breakthrough infections per variant and vaccine type.
    Dingemans J; van der Veer BMJW; Gorgels KMF; Hackert V; den Heijer CDJ; Hoebe CJPA; Savelkoul PHM; van Alphen LB
    Front Microbiol; 2022; 13():1027271. PubMed ID: 36504818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COVID-19 Breakthrough Infection after Inactivated Vaccine Induced Robust Antibody Responses and Cross-Neutralization of SARS-CoV-2 Variants, but Less Immunity against Omicron.
    Suntronwong N; Yorsaeng R; Puenpa J; Auphimai C; Thongmee T; Vichaiwattana P; Kanokudom S; Duangchinda T; Chantima W; Pakchotanon P; Assawakosri S; Nilyanimit P; Klinfueng S; Wongsrisang L; Srimuan D; Thatsanatorn T; Sudhinaraset N; Wanlapakorn N; Poovorawan Y
    Vaccines (Basel); 2022 Mar; 10(3):. PubMed ID: 35335023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coronavirus Disease 2019 (COVID-19) Breakthrough Infection and Post-Vaccination Neutralizing Antibodies Among Healthcare Workers in a Referral Hospital in Tokyo: A Case-Control Matching Study.
    Yamamoto S; Maeda K; Matsuda K; Tanaka A; Horii K; Okudera K; Takeuchi JS; Mizoue T; Konishi M; Ozeki M; Sugiyama H; Aoyanagi N; Mitsuya H; Sugiura W; Ohmagari N
    Clin Infect Dis; 2022 Aug; 75(1):e683-e691. PubMed ID: 34950947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation of neutralizing antibodies against Omicron, Gamma and Delta SARS-CoV-2 variants following CoronaVac vaccination.
    Silva ARD; Villas-Boas LS; Tozetto-Mendoza TR; Honorato L; Paula A; Witkin SS; Mendes-Correa MC
    Rev Inst Med Trop Sao Paulo; 2022; 64():e19. PubMed ID: 35239863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Absence of self-reported neuropsychiatric and somatic symptoms after Omicron variant SARS-CoV-2 breakthrough infections.
    Woo MS; Mayer C; Brehm TT; Andersen G; Weigel A; Löwe B; Lohse AW; Addo MM; Gerloff C; Knobloch JKM; Schulze Zur Wiesch J; Friese MA
    Brain Commun; 2023; 5(2):fcad092. PubMed ID: 37038497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of SARS-CoV-2 genomic surveillance data during the Delta and Omicron waves at a Saudi tertiary referral hospital.
    Obeid D; Al-Qahtani A; Almaghrabi R; Alghamdi S; Alsanea M; Alahideb B; Almutairi S; Alsuwairi F; Al-Abdulkareem M; Asiri M; Alshukairi A; Alkahtany J; Altamimi S; Mutabagani M; Althawadi S; Alanzi F; Alhamlan F
    J Infect Public Health; 2023 Feb; 16(2):171-181. PubMed ID: 36543031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ad5-nCoV booster and Omicron variant breakthrough infection following two doses of inactivated vaccine elicit comparable antibody levels against Omicron variants.
    Kong W; Zhong Q; Chen M; Yu P; Xu R; Zhang L; Lai C; Deng M; Zhou Q; Xiong S; Liang Y; Wan L; Lin M; Wang M; Mai W; Chen L; Lei Y; Qin N; Zhu J; Ruan J; Huang Q; Kang A; Wang J; Li W; Ji T
    J Med Virol; 2023 Jan; 95(1):e28163. PubMed ID: 36127294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody Avidity and Neutralizing Response against SARS-CoV-2 Omicron Variant after Infection or Vaccination.
    Dapporto F; Marchi S; Leonardi M; Piu P; Lovreglio P; Decaro N; Buonvino N; Stufano A; Lorusso E; Bombardieri E; Ruello A; Viviani S; Molesti E; Trombetta CM; Manenti A; Montomoli E
    J Immunol Res; 2022; 2022():4813199. PubMed ID: 36093434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutralizing Activity Against SARS-CoV-2 Delta and Omicron Variants Following a Third BNT162b2 Booster Dose According to Three Homologous or Heterologous COVID-19 Vaccination Schedules.
    Choi JY; Lee YJ; Ko JH; Kim SH; Kim HJ; Lee HW; Jeong H; Kim TY; Jang YG; Hong HJ; Kim MS; Lee SE; Kim YG; Chung EJ; Lim H; Jang S; Kim K; Kim SS; Ahn JY; Choi JY; Kim YC; Park YS; Peck KR; Kim B
    Front Cell Infect Microbiol; 2022; 12():948014. PubMed ID: 35899050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study.
    Gram MA; Emborg HD; Schelde AB; Friis NU; Nielsen KF; Moustsen-Helms IR; Legarth R; Lam JUH; Chaine M; Malik AZ; Rasmussen M; Fonager J; Sieber RN; Stegger M; Ethelberg S; Valentiner-Branth P; Hansen CH
    PLoS Med; 2022 Sep; 19(9):e1003992. PubMed ID: 36048766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.